Indian pharmaceutical exports
Indian Pharma Largely Protected from Trump's 100% Tariffs on Imported Drugs
Sep 26, 2025 04:11 pm CST
President Trump's new 100% tariffs on imported branded pharmaceuticals may have minimal impact on India's drug industry as most major Indian pharma companies already operate manufacturing facilities in the US. With Indian exports to America primarily consisting of generic medications worth $10.5 billion annually, companies like Cipla, Dr Reddy's, and Biocon are strategically positioned to navigate these trade restrictions while stock markets respond cautiously to the announcement.
Trump Announces 100% Tariff on Pharmaceutical Imports Unless Companies Build US Manufacturing Plants
Sep 26, 2025 11:42 am CST
President Donald Trump has announced 100% tariffs on pharmaceutical imports effective October 1, 2025, with exemptions for companies actively constructing manufacturing facilities in the US. The policy could significantly impact India's pharmaceutical sector, which exports over $3.6 billion in products to the US annually. This move follows recent 50% tariffs imposed on India for purchasing Russian oil, as bilateral trade negotiations continue.